<DOC>
	<DOC>NCT00004359</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita. II. Investigate the effect of ECP on lymphocyte activity.</brief_summary>
	<brief_title>Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days. Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Acquisita</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>Active epidermolysis bullosa acquisita</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>dermatologic disorders</keyword>
	<keyword>epidermolysis bullosa</keyword>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>rare disease</keyword>
</DOC>